Title: Full Text of SR0105
Official Title: 
Number of Sections: 1
Source: versions - Introduced
Media Type: text/html

================================================================================

Section 1:
Full Text of SR0105 ILGA.GOV SR0105 - 104th General Assembly SR0105LRB104 10584 LAW 20660 r1SENATE RESOLUTION 2    WHEREAS, Serious mental illnesses like bipolar disorder, 3major depressive disorder, and schizophrenia often require 4treatment with antipsychotic medications for effective 5management, and antipsychotic prescribing rates continue to 6rise; and 7    WHEREAS, While prolonged antipsychotic use may be 8essential for the treatment of certain conditions, it is 9associated with tardive dyskinesia (TD), a condition marked by 10uncontrollable, abnormal, and repetitive movements of the 11face, torso, limbs, or extremities; and 12    WHEREAS, People at higher risk of TD include those older 13than 55 years, people who are Black, women, individuals with 14mood or substance use disorders, intellectual disabilities, or 15central nervous system injuries, and those with high 16cumulative antipsychotic exposure; and 17    WHEREAS, Approximately 60% of the estimated 800,000 U.S. 18adults living with TD remain undiagnosed, and even mild TD 19symptoms can be stigmatizing and impair physical, social, and 20emotional well-being, underscoring the urgency of early 21screening, detection, and intervention; and   SR0105- 2 -LRB104 10584 LAW 20660 r1    WHEREAS, The American Psychiatric Association recommends 2routine TD screening in their clinical guidelines for 3antipsychotic treatment, and individuals treated with 4antipsychotics or experiencing abnormal movements should 5consult their health care providers to assess TD risk, receive 6TD screenings, and determine appropriate treatment together; 7and 8    WHEREAS, FDA-approved treatments for TD can provide 9options for symptom management and improved quality of life 10for many individuals living with TD; and 11    WHEREAS, The General Assembly can encourage TD screening 12education and awareness for health care providers, patients, 13and care partners to help ensure patients prescribed 14antipsychotics receive care and support that aligns with 15clinical best practices, including regular TD screenings; 16therefore, be it 17    RESOLVED, BY THE SENATE OF THE ONE HUNDRED FOURTH GENERAL 18ASSEMBLY OF THE STATE OF ILLINOIS, that we declare May 4 19through May 10, 2025 as Tardive Dyskinesia Awareness Week 20(TDAW) in the State of Illinois; and be it further 21    RESOLVED, That we support TDAW in recognition of the 22importance of early detection and intervention to improve   SR0105- 3 -LRB104 10584 LAW 20660 r1outcomes for people living with mental health conditions and 2prescribed antipsychotics, and we support efforts to raise 3awareness about the causes and symptoms of tardive dyskinesia 4(TD) and the importance of routine TD screening.


================================================================================

Raw Text:
Full Text of SR0105 ILGA.GOV SR0105 - 104th General Assembly SR0105LRB104 10584 LAW 20660 r1SENATE RESOLUTION 2    WHEREAS, Serious mental illnesses like bipolar disorder, 3major depressive disorder, and schizophrenia often require 4treatment with antipsychotic medications for effective 5management, and antipsychotic prescribing rates continue to 6rise; and 7    WHEREAS, While prolonged antipsychotic use may be 8essential for the treatment of certain conditions, it is 9associated with tardive dyskinesia (TD), a condition marked by 10uncontrollable, abnormal, and repetitive movements of the 11face, torso, limbs, or extremities; and 12    WHEREAS, People at higher risk of TD include those older 13than 55 years, people who are Black, women, individuals with 14mood or substance use disorders, intellectual disabilities, or 15central nervous system injuries, and those with high 16cumulative antipsychotic exposure; and 17    WHEREAS, Approximately 60% of the estimated 800,000 U.S. 18adults living with TD remain undiagnosed, and even mild TD 19symptoms can be stigmatizing and impair physical, social, and 20emotional well-being, underscoring the urgency of early 21screening, detection, and intervention; and   SR0105- 2 -LRB104 10584 LAW 20660 r1    WHEREAS, The American Psychiatric Association recommends 2routine TD screening in their clinical guidelines for 3antipsychotic treatment, and individuals treated with 4antipsychotics or experiencing abnormal movements should 5consult their health care providers to assess TD risk, receive 6TD screenings, and determine appropriate treatment together; 7and 8    WHEREAS, FDA-approved treatments for TD can provide 9options for symptom management and improved quality of life 10for many individuals living with TD; and 11    WHEREAS, The General Assembly can encourage TD screening 12education and awareness for health care providers, patients, 13and care partners to help ensure patients prescribed 14antipsychotics receive care and support that aligns with 15clinical best practices, including regular TD screenings; 16therefore, be it 17    RESOLVED, BY THE SENATE OF THE ONE HUNDRED FOURTH GENERAL 18ASSEMBLY OF THE STATE OF ILLINOIS, that we declare May 4 19through May 10, 2025 as Tardive Dyskinesia Awareness Week 20(TDAW) in the State of Illinois; and be it further 21    RESOLVED, That we support TDAW in recognition of the 22importance of early detection and intervention to improve   SR0105- 3 -LRB104 10584 LAW 20660 r1outcomes for people living with mental health conditions and 2prescribed antipsychotics, and we support efforts to raise 3awareness about the causes and symptoms of tardive dyskinesia 4(TD) and the importance of routine TD screening.